Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid
Status:
Terminated
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
This study is intended to investigate the recommended dose of alvimopan in doses 0.25mg/day
(0.25mg, OD), 0.5mg/day (0.25mg, BID) or 1mg/day (0.5mg, BID) or placebo for 3 weeks in
patients who receive opioids for the management of cancer pain and develop constipation, by
giving overall consideration to the efficacy and safety data in each treatment group. Also,
efficacy and safety data of alvimopan in the recommended dose group will be compared with
those of placebo and to confirm alvimopan's safety and efficacy.